Skip to main content

Table 5 Comparisons of NAFLD patients with pericellular fibrosis with NAFLD patients without pericellular fibrosis

From: The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)

Variable

NAFLD without

NAFLD with

P-value

p. fibrosis (N = 152)

p. fibrosis (N = 95)

Age (yrs)

44.03 ± 11.08

46.73 ± 11.35

0.0609

BMI (kg/m2)

48.05 ± 8.94

49.23 ± 10.19

0.1752

WBC (x 103/uL)

8.16 ± 2.35

8.77 ± 9.15

0.5668

Platelets (x 103/uL)

290.32 ± 63.79

267.63 ± 67.91

0.0094

Insulin Resistance

2.42 ± 1.16

8.69 ± 11.25

0.0009

Glucose (mg/dL)

111.01 ± 36.85

120.25 ± 43.34

0.2630

ALT (U/L)

32.38 ± 17.62

49.95 ± 37.96

<.0001

AST (U/L)

23.97 ± 11.78

36.88 ± 30.51

<.0001

Triglycerides (mg/dL)

159.48 ± 86.89

185.17 ± 119.26

0.0760

LDL (mg/dL)

112.12 ± 36.03

109.52 ± 35.33

0.7968

Total cholesterol (mg/dL)

193.96 ± 39.81

188.62 ± 41.43

0.3486

HDL (mg/dL)

48.38 ± 13.47

42.69 ± 11.20

0.0004

Male: N (%)

26 (17.1 %)

45 (47.4 %)

<.0001

White: N (%)

119 (78.3 %)

77 (81.1 %)

0.6017

HAPLOTYPE, N (%)

 H

58 (38.2 %)

35 (36.8 %)

0.8355

 L

24 (15.8 %)

4 (4.2 %)

0.0052

 U

17 (11.2 %)

14 (14.7 %)

0.4123

 Other

13 (8.6 %)

18 (18.9 %)

0.0164

 K

12 (7.9 %)

11 (11.6 %)

0.3324

 J

11 (7.2 %)

5 (5.3 %)

0.5398

 T

10 (6.6 %)

5 (5.3 %)

0.6736

PNPLA3_SNP, N (%)

 CC

94 (61.8 %)

38 (40.0 %)

0.0008

 GC

38 (25.0 %)

52 (54.7 %)

<0.0001

 GG

20 (13.2 %)

5 (5.3 %)

0.0454

  1. For convenience, significant p-values are highlighted by bold font